웹2024년 3월 16일 · Objective . Triple-negative breast cancer (TNBC) accounts for 15–25% of breast cancers. It is increasingly recognized that TNBC is a motley disease. TNBC and … 웹2024년 6월 8일 · Discussion. In the present study we assessed expression of one basal (CK5/6) and one luminal marker (CK8/18) in TNBC in our population and found that; 8 and 2.7% of TNBC showed positive and focal positive expression of CK5/6 respectively and 4.7 and 32.7% of TNBC revealed complete loss and focal loss of CK 8/18 expression …
Clémence Dubois - Directrice du laboratoire BIORCELL3D
웹The most aggressive subtype of breast cancer is basal-like triple negative breast cancer (TNBC), which is associated with a poor prognosis, invasiveness, early relapse, and distant … 웹2024년 12월 30일 · Basal-like TNBC is notorious for a benign appearance on multimodality imaging. Although the majority of TNBCs manifest as an irregularly shaped masses with ill … martin tools wrench set
Full article: Potential Therapeutic Targets for Luminal Androgen …
웹2024년 3월 7일 · Similarly, in the TNBC (CNIO) collection tumors expressing RANK tended to have worse survival in patients receiving chemotherapy, particularly to regimens containing taxanes (Fig EV3D; Dataset EV1). Altogether, these results point out the importance of RANK expression as an independent biomarker of both poor prognosis and chemotherapy … 웹2024년 2월 6일 · Unlike Met(mt) tumors, which are histologically diverse and enriched in a basal-like molecular signature, the majority of Met(mt) tumors with Trp53 loss displayed a spindloid pathology with a distinct molecular signature that resembles the human claudin-low subtype of TNBC, including diminished claudins, an epithelial-to-mesenchymal transition … 웹2024년 4월 8일 · Around 74% of basal-like breast tumors are RB1-positive and may be sensitive to GLUT1 inhibition. Around 20 to 30% of basal tumors have a low expression of RB1 and show less sensitivity to GLUT1 inhibitors [12,174,175]. In the RB1-low subtype of TNBC, RB1 loss activates mitochondrial biogenesis with enhanced OXPHOS rates [174,176]. martin todd sussex